Amgen Inc. AMGN reported first-quarter monetary outcomes after the closing bell Thursday. This is a have a look at the highlights.
The Particulars: Amgen reported quarterly earnings of $3.96 per share, which beat the analyst consensus estimate of $3.87 by 2.33%. The corporate mentioned EPS decreased by 1% as a consequence of larger working and curiosity bills pushed by the Horizon acquisition, partially offset by larger revenues.
The corporate reported quarterly gross sales of $7.447 billion, which beat the analyst consensus estimate of $7.436 billion and represents a 21.98% improve over gross sales of $6.105 billion in the identical interval final yr.
Working revenue elevated from $2.8 billion to $3.1 billion and the working margin decreased 5.1 proportion factors to 43.2%. Product gross sales grew 22%, pushed by 25% quantity progress.
The corporate additionally introduced Arrowhead Prescription drugs, Inc. ARWR obtained a $50-million milestone cost from Royalty Pharma Plc RPRX, triggered after the completion of enrollment of the Section 3 OCEAN(a) – Outcomes Trial of olpasiran, which being performed by Amgen.
“With a lot of our revolutionary merchandise delivering sturdy progress and promising new medicines advancing by our pipeline, we’re enthusiastic about delivering enticing long-term progress,” mentioned Robert A. Bradway, CEO of Amgen.
Outlook: Amgen sees full-year 2024 adjusted earnings of between $19 and $20.20 per share versus the $19.48 Avenue estimate.
Associated Information: Rivian Automotive Receives $827M Incentive Package deal: What’s Going On With Rivian Inventory?
AMGN Worth Motion: In keeping with Benzinga Professional, Amgen shares are up 11.7% after-hours at $311 on the time of publication Thursday.
Picture: Phoenix Locklear from Pixabay.
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
